Kimberley J. Hatfield - Search Results

Year	Number of Results
2005	1
2009	1
2010	4
2011	5
2012	4
2013	3
2014	5
2015	4
2016	3
2017	2
2018	4
2019	2
2020	2
2021	2
2022	5
2023	1
2024	0

1

The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.

Nepstad I, Hatfield KJ, Grønningsæter IS, Reikvam H. Nepstad I, et al. Int J Mol Sci. 2020 Apr 21;21(8):2907. doi: 10.3390/ijms21082907. Int J Mol Sci. 2020. PMID: 32326335 Free PMC article. Review.

2

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.

Reikvam H, Hatfield KJ, Wendelbo Ø, Lindås R, Lassalle P, Bruserud Ø. Reikvam H, et al. Biomolecules. 2022 Mar 24;12(4):492. doi: 10.3390/biom12040492. Biomolecules. 2022. PMID: 35454082 Free PMC article. Review.

3

MicroRNA serum profiles and chronic graft-versus-host disease.

Reikvam H, Vo AK, Johansen S, Hemsing AL, Solheim MH, Mosevoll KA, Tvedt THA, Hatfield KJ. Reikvam H, et al. Blood Adv. 2022 Sep 27;6(18):5295-5306. doi: 10.1182/bloodadvances.2021005930. Blood Adv. 2022. PMID: 35443023 Free PMC article.

4

High-dose etoposide in allogeneic stem cell transplantation.

Bruserud O, Reikvam H, Kittang AO, Ahmed AB, Tvedt TH, Sjo M, Hatfield KJ. Bruserud O, et al. Cancer Chemother Pharmacol. 2012 Dec;70(6):765-82. doi: 10.1007/s00280-012-1990-z. Epub 2012 Oct 6. Cancer Chemother Pharmacol. 2012. PMID: 23053272 Review.

5

STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.

Bruserud Ø, Nepstad I, Hauge M, Hatfield KJ, Reikvam H. Bruserud Ø, et al. Expert Rev Hematol. 2015 Feb;8(1):29-41. doi: 10.1586/17474086.2015.971005. Epub 2014 Nov 6. Expert Rev Hematol. 2015. PMID: 25374305 Review.

6

Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?

Hauge M, Bruserud Ø, Hatfield KJ. Hauge M, et al. Eur J Haematol. 2016 Mar;96(3):211-21. doi: 10.1111/ejh.12690. Epub 2015 Nov 26. Eur J Haematol. 2016. PMID: 26465810 Review.

7

Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.

Kallekleiv M, Larun L, Bruserud Ø, Hatfield KJ. Kallekleiv M, et al. Cytotherapy. 2016 Feb;18(2):172-85. doi: 10.1016/j.jcyt.2015.11.010. Cytotherapy. 2016. PMID: 26794711 Review.

8

Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.

Reikvam H, Hauge M, Brenner AK, Hatfield KJ, Bruserud Ø. Reikvam H, et al. Expert Rev Hematol. 2015 Jun;8(3):299-313. doi: 10.1586/17474086.2015.1032935. Epub 2015 Apr 3. Expert Rev Hematol. 2015. PMID: 25835070 Review.

9

Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients.

Hatfield KJ, Bruserud Ø, Reikvam H. Hatfield KJ, et al. Cancers (Basel). 2022 Jun 13;14(12):2910. doi: 10.3390/cancers14122910. Cancers (Basel). 2022. PMID: 35740576 Free PMC article.

10

NPM1-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition.

Hemsing AL, Rye KP, Hatfield KJ, Reikvam H. Hemsing AL, et al. Biomedicines. 2022 Aug 4;10(8):1881. doi: 10.3390/biomedicines10081881. Biomedicines. 2022. PMID: 36009428 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

41 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year